Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 25;60(4):2551-3.
doi: 10.1128/AAC.02859-15. Print 2016 Apr.

The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri

Evgeny A Idelevich  1 , Frieder Schaumburg  1 , Dennis Knaack  1 , Anna S Scherzinger  2 , Wolfgang Mutter  2 , Georg Peters  1 , Andreas Peschel  3 , Karsten Becker  4
Affiliations

The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri

Evgeny A Idelevich et al. Antimicrob Agents Chemother. .

Abstract

HY-133 is a recombinant bacteriophage endolysin with bactericidal activity againstStaphylococcus aureus Here, HY-133 showedin vitroactivity against major African methicillin-susceptible and methicillin-resistantS. aureuslineages and ceftaroline/ceftobiprole- and borderline oxacillin-resistant isolates. HY-133 was also active againstStaphylococcus schweitzeri, a recently described species of theS. aureuscomplex. The activity of HY-133 on the tested isolates (MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml; range, 0.125 to 0.5 μg/ml) was independent of the species and strain background or antibiotic resistance.

PubMed Disclaimer

References

    1. Schmelcher M, Donovan DM, Loessner MJ. 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147–1171. doi: 10.2217/fmb.12.97. - DOI - PMC - PubMed
    1. Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP. 2013. MRSA in Africa: filling the global map of antimicrobial resistance. PLoS One 8:e68024. doi: 10.1371/journal.pone.0068024. - DOI - PMC - PubMed
    1. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K. 2011. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother 55:4416–4419. doi: 10.1128/AAC.00217-11. - DOI - PMC - PubMed
    1. Knaack D, Idelevich EA, Schleimer N, Scherzinger AS, Kriegeskorte A, Peters G, Mutter W, Becker K. 2015. In vitro activity of recombinant chimeric bacteriophage endolysins against Staphylococcus aureus under different growth conditions. 25th European Conference of Clinical Microbiology and Infectious Diseases ESCMID Online Lecture Library, no. P0727.
    1. Tong SY, Schaumburg F, Ellington MJ, Corander J, Pichon B, Leendertz F, Bentley SD, Parkhill J, Holt DC, Peters G, Giffard PM. 2015. Novel staphylococcal species that form part of a Staphylococcus aureus-related complex: the non-pigmented Staphylococcus argenteus sp. nov. and the non-human primate-associated Staphylococcus schweitzeri sp. nov. Int J Syst Evol Microbiol 65:15–22. doi: 10.1099/ijs.0.062752-0. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources